Who are Amivantamab Intravenous's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Savolitinib + Osimertinib, BAT8001 for injection, SHR-A2009 monotherapy, GST-HG141, Ponatinib + Blinatumomab, VB4-845 Injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amivantamab-intravenous.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Amivantamab Intravenous — Competitive Intelligence Brief

Amivantamab Intravenous (Amivantamab Intravenous) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific monoclonal antibody. Area: Oncology.

phase 3 Bispecific monoclonal antibody EGFR and MET Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Amivantamab Intravenous (Amivantamab Intravenous) — Janssen Research & Development, LLC. Amivantamab is a bispecific monoclonal antibody that simultaneously binds to EGFR and MET receptors, blocking their signaling and triggering immune-mediated tumor cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Amivantamab Intravenous TARGET	Amivantamab Intravenous	Janssen Research & Development, LLC	phase 3	Bispecific monoclonal antibody	EGFR and MET
Savolitinib + Osimertinib	Savolitinib + Osimertinib	Hutchison Medipharma Limited	phase 3	Tyrosine kinase inhibitor combination	EGFR and MET
BAT8001 for injection	BAT8001 for injection	Bio-Thera Solutions	phase 3	Bispecific monoclonal antibody
SHR-A2009 monotherapy	SHR-A2009 monotherapy	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	phase 3	Bispecific monoclonal antibody
GST-HG141	GST-HG141	Fujian Akeylink Biotechnology Co., Ltd.	phase 3	Bispecific monoclonal antibody
Ponatinib + Blinatumomab	Ponatinib + Blinatumomab	Gruppo Italiano Malattie EMatologiche dell'Adulto	phase 3	Tyrosine kinase inhibitor, Bispecific monoclonal antibody	BCR-ABL1, CD19, CD3
VB4-845 Injection	VB4-845 Injection	Qilu Pharmaceutical Co., Ltd.	phase 3	Bispecific monoclonal antibody	VEGF and HER2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific monoclonal antibody class)

Akeso · 1 drug in this class
Bio-Thera Solutions · 1 drug in this class
Fujian Akeylink Biotechnology Co., Ltd. · 1 drug in this class
Janssen Research & Development, LLC · 1 drug in this class
Qilu Pharmaceutical Co., Ltd. · 1 drug in this class
Shanghai JMT-Bio Inc. · 1 drug in this class
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 drug in this class
Xianmin Song, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Amivantamab Intravenous — Competitive Intelligence Brief. https://druglandscape.com/ci/amivantamab-intravenous. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab